Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Non-Current Liabilities (2018 - 2025)

Corcept Therapeutics (CORT) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 7.75% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.2 million through Dec 2025, up 7.75% year-over-year, with the annual reading at $15.2 million for FY2025, 7.75% up from the prior year.
  • Other Non-Current Liabilities hit $15.2 million in Q4 2025 for Corcept Therapeutics, up from $14.1 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $15.7 million in Q2 2025 to a low of $403000.0 in Q2 2021.
  • Historically, Other Non-Current Liabilities has averaged $8.7 million across 5 years, with a median of $10.1 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: rose 1.77% in 2021 and later skyrocketed 2124.21% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $409000.0 in 2021, then surged by 2124.21% to $9.1 million in 2022, then rose by 13.3% to $10.3 million in 2023, then skyrocketed by 36.64% to $14.1 million in 2024, then rose by 7.75% to $15.2 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for CORT at $15.2 million in Q4 2025, $14.1 million in Q3 2025, and $15.7 million in Q2 2025.